Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Molecular dissection of the roles of the Hippo pathway in embryonic stem cell fate decision

EF 2010-11

Résumé
While the adult body is composed of differentiated cell types specific to each organ, the cells of the developing embryo or embryonic stem (ES) cells, are still in an undifferentiated state (pluripotency), where they still have the potential to differentiate in almost any cell type of the body. In the past few years the concept of regenerative medicine, a promising therapeutic approach based on our ability to repair damaged organs, has emerged as a potentially viable method to improve a variety of human health issues such as diabetes, leukemias, muscular dystrophy or nerve injuries. Our ability to successfully bring this approach to the clinic is directly linked to our understanding of how these pluripotent ES cells undergo cellular lineage fate decisions to become a specific cell type. Recently, a cellular pathway involved in the control of organ size in mice, the Hippo pathway, has been associated with the maintenance of the pluripotency state of ES cells. This pathway is acting mainly via two essential proteins, Yap and Taz. We believe that these regulators of gene expression are potential candidates for the development of ES-cell based therapies. The goal of the proposed project is to decipher the precise mechanisms by which Yap and Taz control the ES cells switch from pluripotency to a more specialized state. The findings generated from this study will increase our understanding of the ES cells commitment process and potentially extend our ability to eventually manipulate ES cell fate for the achievement of successful regenerative medicine therapies.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
214753
Name
Tremblay Annie
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Molecular dissection of the roles of the Hippo pathway in embryonic stem cell fate decision
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aging; Cell Biology; Chip-Sequencing; Embryonic Stem Cells; Gene Regulation; Mass Spectrometry; Mouse Models; Pluripotency; Tissue Regeneration; Transcriptional Regulators
Abstract
While the adult body is composed of differentiated cell types specific to each organ, the cells of the developing embryo or embryonic stem (ES) cells, are still in an undifferentiated state (pluripotency), where they still have the potential to differentiate in almost any cell type of the body. In the past few years the concept of regenerative medicine, a promising therapeutic approach based on our ability to repair damaged organs, has emerged as a potentially viable method to improve a variety of human health issues such as diabetes, leukemias, muscular dystrophy or nerve injuries. Our ability to successfully bring this approach to the clinic is directly linked to our understanding of how these pluripotent ES cells undergo cellular lineage fate decisions to become a specific cell type. Recently, a cellular pathway involved in the control of organ size in mice, the Hippo pathway, has been associated with the maintenance of the pluripotency state of ES cells. This pathway is acting mainly via two essential proteins, Yap and Taz. We believe that these regulators of gene expression are potential candidates for the development of ES-cell based therapies. The goal of the proposed project is to decipher the precise mechanisms by which Yap and Taz control the ES cells switch from pluripotency to a more specialized state. The findings generated from this study will increase our understanding of the ES cells commitment process and potentially extend our ability to eventually manipulate ES cell fate for the achievement of successful regenerative medicine therapies.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tremblay, Annie
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~